Vindhya Organics Private Limited - Due diligence report

A 360° intelligence report on Vindhya Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signals…

1988-01-29 Bollaram, Telangana Amalgamated Unlisted Active Compliant
Share
Connect MCP
VO Vindhya Organics Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Vindhya Pharma — 360° Intelligence Report

Generated from MCA filings & public records
64/100
Trust Score
Moderate

Vindhya Pharma is assessed as Moderate with a Trust Score of 64/100. Vindhya Pharma is a private limited indian non-government company incorporated in 1988, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and moderate financial risk profile.

Report generated on 05 Aug 2026 from the latest processed filings. Vindhya Organics Private Limited snapshot & full profile →

Financial Health › Good
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Weak

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
64/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
35/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
65/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
60/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
55/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.
  • No open charges - unencumbered balance sheet.
  • Elevated gearing (D/E 1.42).
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 14 satisfied (29.78 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Axis Bank Limited2 48.0 cr
State Bank Of Hyderabad3 48.0 cr
Others1 48.0 cr
The Industrial Credit & Investment Corpn. Of India Ltd.1 48.0 cr
Andhra Pradesh Industrial Development Corporation2 48.0 cr
A.P.S.F.C.1 48.0 cr
Compliance Score: 35/100 Caution Indicated
  • Company status is "Amalgamated" - not Active.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 3 court forum(s).
  • 1 active GST registration(s).
Legal cases on record (3)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
SRINIVAS VASIREDDY 01234567 Director 01/04/2018 6 yrs Approved
VENUGOPAL GHANTA 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
Director & KMP remuneration (FY 2022)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2025 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Geninn Life Sciences Private Limited
Subsidiaries
-
Group entities
-
Capital events
1 allotment(s) · 1 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Geninn Life Sciences Private Limited Holding Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 60 · Distress 55
Growth signals & trust indicators
Profit expanded 2.1x year-on-year.
Asset base grew 24% - capacity expansion.
Net margin improved to 0.86.
Operating for 38+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 61% in a year.
Adverse company status: Amalgamated.
Compliance score is weak (35/100).
3 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence50/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment48/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance gaps should be priced into terms.
Investor view63/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
18 Jul 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
15 Mar 2025
Charge satisfied
Others
27 Dec 2022
Director ceased
SRINIVAS VASIREDDY
22 Oct 2022
Director appointed
SRINIVAS VASIREDDY (Director)
24 Jan 2022
Director appointed
VENUGOPAL GHANTA (Director)
31 Dec 2021
Director ceased
VENUGOPAL GHANTA
23 Jun 2021
Charge created
Others - 1.39 cr
31 Mar 2021
Share transfer (FY 2021)
10.00000000 shares to Srihari Raju Kalidindi
18 Nov 2020
Charge satisfied
Pennar Paterson Securities Ltd.
21 Sep 2020
Charge satisfied
Axis Bank Limited
30 May 2020
Charge satisfied
Axis Bank Limited
28 Sep 2019
Director ceased
KALIDINDI SRIHARI RAJU
26 Aug 2019
Director ceased
POCHA BRAHMANANDA REDDY
17 Mar 2015
Charge created
Axis Bank Limited - 2.75 cr
10

Key Observations

Auto-generated from the data above
Revenue declined 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Debt-to-equity stands at 24% - leverage worth monitoring.
Net worth is positive.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
All 14 registered charge(s) stand satisfied - past borrowings repaid.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Kanex U24111GJ1986PLC008699 Sihor, Gujarat, India
Cotec Healthcare U24232UT1998PLC016093 Roorkee, Uttarakhand, India
Rv Lifesciences Limited U24230MH1991PLC063442 Aurangabad, Maharashtra, India
Mpm Private Limited U24110MH1996PTC095899 Nagpur, Maharashtra, India
Ambani Organics L24220MH1985PLC036774 Thane, Maharashtra, India
Sarna Chemicals U24231GJ1988PTC010722 Vapi, Gujarat, India
Vision Products Private Limited U15140GJ2005PTC045893 Vadodara, Gujarat, India
Jipl U33114KA1994PTC015825 Bangalore, Karnataka, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Vindhya Pharma before audits and certifications: compliance score 35/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Vindhya Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 60/100, margin trends, ownership structure and peer set for Vindhya Pharma - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 64/100, distress signals and MSME payment-delay disclosures - know whether Vindhya Pharma pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Vindhya Pharma - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Vindhya Pharma an active company?

Vindhya Pharma has MCA status “Amalgamated” with a compliance score of 35/100 (Caution Indicated).

Is Vindhya Pharma financially healthy?

Vindhya Pharma has a Financial Health Score of 65/100 (Moderate) based on its filed financial statements.

Should I do business with Vindhya Pharma?

Its overall Trust Score is 64/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Vindhya Pharma?

The ultimate holding entity is Geninn Life Sciences Private Limited. 2 active director(s) are on record.

Does Vindhya Pharma have loans or charges against its assets?

No open charges - all 14 registered charge(s) stand satisfied, indicating past borrowings were repaid.

Is Vindhya Pharma up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 35/100 (Caution Indicated).

Is it risky to lend to Vindhya Pharma?

Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.